Zacks Research Brokers Lift Earnings Estimates for TSE:BHC

Bausch Health Companies Inc. (TSE:BHC) – Stock analysts at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for shares of Bausch Health Companies in a research note issued to investors on Friday, July 24th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.35 for the quarter, up from their prior estimate of $1.31. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $5.54 EPS and Q1 2027 earnings at $1.13 EPS.

Bausch Health Companies (TSE:BHC) last released its earnings results on Wednesday, April 29th. The company reported C$1.08 earnings per share for the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.The company had revenue of C$3.51 billion during the quarter.

Separately, Jefferies Financial Group upgraded Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 22nd. Three analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Bausch Health Companies Price Performance

Bausch Health Companies stock opened at C$6.25 on Monday. Bausch Health Companies has a 12-month low of C$6.10 and a 12-month high of C$11.97. The company has a quick ratio of 0.58, a current ratio of 1.32 and a debt-to-equity ratio of -1,009.96. The business’s 50-day simple moving average is C$7.02 and its 200 day simple moving average is C$7.66. The stock has a market cap of C$2.33 billion, a price-to-earnings ratio of -1.93, a P/E/G ratio of 0.21 and a beta of 0.97.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.